Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Bristol-Myers Squibb Company

NYSE

Market Cap.

83.6B

Avg. Volume

15.5M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Bristol-Myers Squibb Company!

Still processing it, give me a bit more time...

Bristol-Myers Squibb Company News

Bristol-Myers Squibb Company Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
bms.com

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb Company Earnings & Revenue

Bristol-Myers Squibb Company Financials

Table Compare

Compare BMY metrics with:

   

Earnings & Growth

BMY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BMY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BMY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BMY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Bristol-Myers Squibb Company Income

Bristol-Myers Squibb Company Balance Sheet

Bristol-Myers Squibb Company Cash Flow

Bristol-Myers Squibb Company Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioSell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Bristol-Myers Squibb Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

2.3400

Payment DateDividendFrequency
2024-05-010.6Quarterly
2024-02-010.6Quarterly
2023-11-010.57Quarterly
2023-08-010.57Quarterly
2023-05-010.57Quarterly

Historical Market Cap

Shares Outstanding

Bristol-Myers Squibb Company Executives

NameRole
Dr. Christopher S. Boerner Ph.D.Chief Executive Officer & Chairman
Mr. Samit Hirawat M.D.Executive Vice President, Chief Medical Officer & Head of Development
Ms. Sandra Leung Esq.Executive Vice President & General Counsel
Mr. David V. ElkinsExecutive Vice President & Chief Financial Officer
Ms. Kimberly M. JablonskiChief Compliance & Ethics Officer
NameRoleGenderDate of BirthPay
Dr. Christopher S. Boerner Ph.D.Chief Executive Officer & Chairman19713.14M
Mr. Samit Hirawat M.D.Executive Vice President, Chief Medical Officer & Head of DevelopmentMale19692.62M
Ms. Sandra Leung Esq.Executive Vice President & General CounselFemale19612.58M
Mr. David V. ElkinsExecutive Vice President & Chief Financial OfficerMale19682.28M
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerFemale

--

Bristol-Myers Squibb Company Insider Trades

Date1 May
NameLenkowsky Adam
RoleEVP, Chief Commercial Officer
TransactionDisposed
TypeJ-Other
Shares1373
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionAcquired
TypeM-Exempt
Shares3306
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionDisposed
TypeF-InKind
Shares1196
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionDisposed
TypeM-Exempt
Shares3306
Date31 Mar
NameYALE PHYLLIS R
RoleDirector
TransactionAcquired
TypeA-Award
Shares645.399
DateNameRoleTransactionTypeShares
1 MayLenkowsky AdamEVP, Chief Commercial OfficerDisposedJ-Other1373
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyAcquiredM-Exempt3306
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyDisposedF-InKind1196
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyDisposedM-Exempt3306
31 MarYALE PHYLLIS RDirectorAcquiredA-Award645.399

Discover More

Streamlined Academy

Bristol-Myers Squibb Company

NYSE

Market Cap.

83.6B

Avg. Volume

15.5M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Bristol-Myers Squibb Company News

Bristol-Myers Squibb Company Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Bristol-Myers Squibb Company Earnings & Revenue

Bristol-Myers Squibb Company Income

Bristol-Myers Squibb Company Balance Sheet

Bristol-Myers Squibb Company Cash Flow

Bristol-Myers Squibb Company Financials Over Time

Bristol-Myers Squibb Company Executives

NameRole
Dr. Christopher S. Boerner Ph.D.Chief Executive Officer & Chairman
Mr. Samit Hirawat M.D.Executive Vice President, Chief Medical Officer & Head of Development
Ms. Sandra Leung Esq.Executive Vice President & General Counsel
Mr. David V. ElkinsExecutive Vice President & Chief Financial Officer
Ms. Kimberly M. JablonskiChief Compliance & Ethics Officer
NameRoleGenderDate of BirthPay
Dr. Christopher S. Boerner Ph.D.Chief Executive Officer & Chairman19713.14M
Mr. Samit Hirawat M.D.Executive Vice President, Chief Medical Officer & Head of DevelopmentMale19692.62M
Ms. Sandra Leung Esq.Executive Vice President & General CounselFemale19612.58M
Mr. David V. ElkinsExecutive Vice President & Chief Financial OfficerMale19682.28M
Ms. Kimberly M. JablonskiChief Compliance & Ethics OfficerFemale

--

Bristol-Myers Squibb Company Insider Trades

Date1 May
NameLenkowsky Adam
RoleEVP, Chief Commercial Officer
TransactionDisposed
TypeJ-Other
Shares1373
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionAcquired
TypeM-Exempt
Shares3306
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionDisposed
TypeF-InKind
Shares1196
Date1 Apr
NameShanahan Karin
RoleEVP, Glob. Prod. Dev. & Supply
TransactionDisposed
TypeM-Exempt
Shares3306
Date31 Mar
NameYALE PHYLLIS R
RoleDirector
TransactionAcquired
TypeA-Award
Shares645.399
DateNameRoleTransactionTypeShares
1 MayLenkowsky AdamEVP, Chief Commercial OfficerDisposedJ-Other1373
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyAcquiredM-Exempt3306
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyDisposedF-InKind1196
1 AprShanahan KarinEVP, Glob. Prod. Dev. & SupplyDisposedM-Exempt3306
31 MarYALE PHYLLIS RDirectorAcquiredA-Award645.399

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
bms.com

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Bristol-Myers Squibb Company!

Still processing it, give me a bit more time...

Bristol-Myers Squibb Company Financials

Table Compare

Compare BMY metrics with:

   

Earnings & Growth

BMY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BMY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BMY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BMY

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Bristol-Myers Squibb Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

2.3400

Payment DateDividendFrequency
2024-05-010.6Quarterly
2024-02-010.6Quarterly
2023-11-010.57Quarterly
2023-08-010.57Quarterly
2023-05-010.57Quarterly

Bristol-Myers Squibb Company Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioSell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More